__NUXT_JSONP__("/drugs/Vebreltinib", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1440964-89-5",chebiId:b,chemicalFormula:b,definition:"An orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, vebreltinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.",fdaUniiCode:"2WZP8A9VFN",identifier:"C129717",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C129825","C143099"],synonyms:["6-(1-Cyclopropyl-1h-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5-yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine","APL-101","APL101","Bozitinib","CBI-3103","CBT-101","PLB-1001","PLB1001","VEBRELTINIB",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FVebreltinib",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Vebreltinib","","2021-10-30T13:31:15.053Z")));